SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
SEC Accession No. 0001104659-24-054115
Filing Date
2024-04-29
Accepted
2024-04-29 16:46:03
Documents
17
Period of Report
2023-12-31

Document Format Files

Seq Description Document Type Size
1 FORM 10-K/A tm2412573d1_10ka.htm   iXBRL 10-K/A 394444
2 EXHIBIT 14.1 tm2412573d1_ex14-1.htm EX-14.1 76020
3 EXHIBIT 31.1 tm2412573d1_ex31-1.htm EX-31.1 11872
4 EXHIBIT 31.2 tm2412573d1_ex31-2.htm EX-31.2 11877
  Complete submission text file 0001104659-24-054115.txt   831408

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA nrxp-20231231.xsd EX-101.SCH 3263
6 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE nrxp-20231231_def.xml EX-101.DEF 28404
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE nrxp-20231231_lab.xml EX-101.LAB 39125
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nrxp-20231231_pre.xml EX-101.PRE 27013
21 EXTRACTED XBRL INSTANCE DOCUMENT tm2412573d1_10ka_htm.xml XML 8672
Mailing Address 1201 ORANGE STREET SUITE 600 WILMINGTON DE 19801
Business Address 1201 ORANGE STREET SUITE 600 WILMINGTON DE 19801 484-254-6134
NRX Pharmaceuticals, Inc. (Filer) CIK: 0001719406 (see all company filings)

IRS No.: 822844431 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K/A | Act: 34 | File No.: 001-38302 | Film No.: 24891977
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)